Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enlivex Therapeutics Ltd. - Ordinary Shares (NQ:ENLV)

1.030 +0.130 (+14.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Enlivex Therapeutics Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 Next >
Enlivex: Meet The Company Championing A Paradigm Shift In Cancer Treatment
Sign up for this week’s All Access giveaway here! 
Via Benzinga
Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex to Present at the 37th Annual Meeting of the Society For Immunotherapy Of Cancer
From Enlivex Therapeutics Ltd
Via GlobeNewswire
A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced that Israel, Spain and Greece have cleared amendments to the company’s Phase II trial protocol that will allow the study to enroll more patients. 
Via Benzinga
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds. 
Via Benzinga
Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors
The Israeli Ministry of Health (MOH) approved a Phase I/II trial of Enlivex Therapeutics Ltd.’s (NASDAQ: ENLV) proprietary immunothera 
Via Benzinga
Enlivex to Present at the 4th Macrophage-Directed Therapies Summit
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Roger Pomerantz And Shai Novik Say They're Racing To Change The Odds Of Cancer Treatments
Cancer research has come a long way in the past few decades, pioneering treatments like chemotherapy and radiation treatments that have become essential weapons in the fight against this deadly and... 
Via Benzinga
Changing The Landscape Of Cancer Therapy With Macrophages? How One Israeli Company Reports It's Looking To Do Just That
One of the chief challenges cancer researchers face today is finding a way to outsmart the disease’s defense mechanisms. 
Via Benzinga
Reprogramming Imbalanced Macrophage Populations May Play A Key Role In Resolving Cancer And Various Inflammatory Disorders
Shai Novik, Executive Chairman of the Board at Enlivex Therapeutics, Ltd. (NASDAQ: ENLV), was a guest speaker at Benzinga’s All Access on June 17th, 2022. 
Via Benzinga
Monkeypox Could Reportedly Trigger An Uptick In Sepsis Cases But This Israeli Biotech Company Says It May Have Found A Treatment
As the mysterious monkeypox outbreak has many scientists on heightened alert, the rare virus could pose an additional threat to a global population still reeling from the COVID-19 pandemic. 
Via Benzinga
Will Another Enlivex Innovation Break The Glass Ceiling For Solid Tumor Treatments?
Cell therapy — the use of stem cells and various engineered immune cells to target difficult-to-treat diseases like cancer and autoimmune conditions — has arguably been one of the big breakthroughs in... 
Via Benzinga
Should Biotech Be On The Critical List?
The risk-off market has played havoc with the biotechs where the fundamentals have not changed as much as the valuation. 
Via Talk Markets
51 Biggest Movers From Yesterday
Gainers Advent Technologies Holdings, Inc. (NASDAQ: ADN) shares climbed 79.7% to close at $3.63 on Wednesday. Advent Technologies and Hyundai Motor Company entered into... 
Via Benzinga
World Markets News For Thursday
Ericsson stock lost another 5.27% today in US markets. 
Via Talk Markets
Inflation inflating
The Fed will be raising interest rates soon and this will chop the appeal of investments in more vulnerable yield plays. 
Via Talk Markets
Weakened Tech Stocks
There was a 0.5% rise in UK interest rates, twice what had been anticipated and moreover early, because of inflation risks. 
Via Talk Markets
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 105 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows And Highs: Meta Platforms (NASDAQ:FB) was the biggest company on... 
Via Benzinga
Drug Troubles
The drug sector has both good news and bad. 
Via Talk Markets
Market Trend: Erratic And Unreliable
Given the risks of covid variants and hefty price rises, the stock market should not be as buoyant as it is. 
Via Talk Markets
Tuesday Markets Coverage
GE was up on hopes for cheaper oil. But most stocks were down on oil price hike fears. 
Via Talk Markets
Wednesday Market Overview
Inflation came in at 6.2% in October which boosted gold and of course the new hedge, bitcoin 
Via Talk Markets
Election Day
Teva rose a whopping 8.34% today. 
Via Talk Markets
A Bit Of A Recovery
While Germany remains without a government, Japan has a new prime minister who will lead his party in the election this week. 
Via Talk Markets
China's Rescue Of Evergrand
The number of jobless last week was higher than the forecast, at 351,000 vs 320,000. The recovery is lagging. 
Via Talk Markets
54 Biggest Movers From Yesterday
Gainers Focus Universal Inc. (NASDAQ: FCUV) shares climbed 278% to close at $19.28 on Wednesday. The stock started trading on Nasdaq Capital Market yesterday. Sequential Brands... 
Via Benzinga
Vaccine Victory
Monday the US stock market moved into further robust mode fueled by official FDA approval of the Pfizer and BioNTech COVID-19 vaccines. Will the momentum last through to Thursday when the Fed's Jackson... 
Via Talk Markets
Topics Economy
Exposures COVID-19 Interest Rates Product Safety
55 Biggest Movers From Yesterday
Gainers Unico American Corporation (NASDAQ: UNAM) shares gained 59% to close at $4.15 on Tuesday. Elys Game Technology, Corp. (NASDAQ: ELYS) rose 43% to close at $6.62 after it... 
Via Benzinga
Now That The FDA Approved Pfizer-BioNTech, Is This It For Vaccine Stocks?
If there's one thing to take away from any conversation about biotech stocks, it's that any company with their hat in the ring is likely making a version of something they hope to be better than the... 
Via Talk Markets
Exposures Product Safety
60 Biggest Movers From Yesterday
Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares jumped 33.7% to close at $3.37 on Monday after the company announced plan to expand product portfolio with introduction of... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.